The epidemiology of Exophiala xenobiotica needs to be better understood. Still, some studies have suggested that it is widely distributed in the environment, especially in habitats rich in hydrocarbons and alkanes, such as oil-contaminated soils, wastewater, and biofilters. It has also been detected in the respiratory tracts of cystic fibrosis patients. and the skin of fish. The prevalence of Exophiala xenobiotica infections is likely underestimated, as it is morphologically very similar to E. jeanselmei and requires molecular methods for accurate identification.
The risk factors for acquiring Exophiala xenobiotica infections are not well defined, but they may include exposure to contaminated environments, immunosuppression, chronic lung diseases, and surgical procedures. The global distribution and incidence of Exophiala xenobiotica infections are unknown, but most cases have been reported in Europe, Asia, and North America. More studies are needed to elucidate the ecology, transmission, and pathogenicity of this emerging fungal agent.
The prevalence and mortality rate of Exophiala xenobiotica infections has yet to be well known, as this is a relatively new species that was described in 2006. However, some studies have reported a few cases of human and animal infections caused by this fungus. For example, a study from India identified one isolate of E. xenobiotica among 24 Exophiala isolates from various clinical specimens.
Another study from China reported two cases of cutaneous infections by E. xenobiotica in immunocompetent patients. A third study from Germany described a case of fatal disseminated infection by E. xenobiotica in a patient with chronic granulomatous disease. The mortality rate of E. xenobiotica infections may depend on the type and extent of infection, the immune status of the host, and the response to antifungal therapy.
Classification and Structure
Kingdom: Fungi
Phylum: Ascomycota
Class: Eurotiomycetes
Order: Chaetothyriales
Family: Herpotrichiellaceae
Genus:Exophiala
Species: E. xenobiotica
The structure of Exophiala xenobiotica can be summarized in five points as follows:
Exophiala xenobiotica is a species of black yeast that belongs to the Exophiala jeanselmei complex.
It produces black, velvety colonies on Sabouraud dextrose agar and has darkly pigmented, annellidic conidiogenous cells and oval to cylindrical conidia.
It has a protein crystal structure of an amine transaminase, which is an enzyme that catalyzes the conversion of biaryl ketones to amines.
It has two antigenic types, A and B, according to the internal transcribed spacer (ITS) region’s sequence analysis of the ribosomal DNA. Type A is more common and widely distributed than type B.
It is phylogenetically related to other Exophiala species and other members of the Herpotrichiellaceae family, which are opportunistic black yeast-like fungi.
The antigenic types of Exophialaxenobiotica are not well studied, but based on the results from the web search; it seems that this species is a segregant of the Exophialajeanselmeicomplex, which has two antigenic types: type A and The ITS sequence phylogram of E. jeanselmei revealed that most isolates formed a separate cluster close to type A, while some isolates were like type B.
E. xenobiotica may have a similar antigenic diversity, but more research is needed to confirm this hypothesis. Antigenic types are essential for the diagnosis and treatment of Exophiala infections, as they may reflect different virulence and antifungal susceptibility patterns.
The pathogenesis of Exophialaxenobiotica is not well understood, but it is known that it can cause cutaneous infections in humans, especially in immunocompromised individuals. It can also infect animals, such as crocodile fish and rabbit fish, and cause systemic infections of the liver and kidney.
The fungus may enter the host through wounds or abrasions on the skin or through inhalation of spores. It may produce toxins or enzymes that damage the host tissues or evade the host immune system by forming melanin pigments or biofilms.
The fungus may also have different antigenic types, A and B, that may affect its pathogenicity, ecology, and epidemiology. However, more studies are needed to confirm this hypothesis and to elucidate the molecular mechanisms of infection byExophialaxenobiotica.
The host defenses to Exophiala xenobiotica are not well studied, but some general aspects of the immune response to black yeasts can be mentioned. Black yeasts can evade or resist the host defenses by producing melanin pigments, biofilms, and extracellular enzymes. Melanin protects the fungal cells from oxidative stress, phagocytosis, and antifungal drugs.
Biofilms enhance the adherence and persistence of the fungus on the host surfaces and reduce the penetration of antimicrobial agents1. Extracellular enzymes, such as lipases, proteases, and phospholipases, may degrade the host tissues and facilitate the invasion and dissemination of the fungus.
The host defenses against black yeasts involve both innate and adaptive immunity. Skin and mucous membranes are examples of physical barriers that are a part of innate immunity and cellular and molecular components, such as neutrophils, macrophages, natural killer cells, complement, and cytokines. The adaptive immunity includes humoral and cellular responses, like T cells, B cells, and antibodies.
The role of these immune components in the defense against Exophiala xenobiotica needs to be clarified. Still, some studies have suggested that T lymphocytes, neutrophils, and macrophages could all be involved in the clearance or containment of the infection. However, the immune response may also cause tissue damage and inflammation, which may contribute to the pathogenesis of the infection.
The host defenses to Exophiala xenobiotica may also depend on the host factors, such as the genetic background, the immune status, and the underlying diseases of the host. For example, immunocompromised individuals, such as those with HIV infection, organ transplantation, or cancer, may have a higher susceptibility and a worse prognosis of the infection.
On the other hand, some individuals may have a natural resistance or protective immunity to the infection, which may be related to their genetic polymorphisms or previous exposure to the fungus.Therefore, the host defenses to Exophiala xenobiotica are complex and variable, and more research is needed to comprehend the components and processes involved in the interaction between the host and the fungus.
Black yeast Exophiala xenobiotica is a member of the Exophiala jeanselmei complex. This pathogen is opportunistic and can infect both humans and animals, especially in immunocompromised hosts.
The clinical manifestations of Exophiala xenobiotica infections differ according to the location and severity of the infection. Several potential expressions
are:
Cutaneous infections: These are usually caused by traumatic inoculation of the fungus into the skin. They can present as nodules, ulcers, verrucous lesions, or cysts. Sometimes, the lesions can mimic benign epidermoid cysts.
Subcutaneous infections: These are deeper infections that involve the subcutaneous tissue, muscle, or bone. They can result from direct extension of cutaneous infections or hematogenous dissemination. They can cause mycetoma, osteomyelitis, arthritis, or abscesses.
Systemic infections: These are rare but life-threatening infections that impact several organs, including the lungs, liver, spleen, brain, kidneys, and heart. They can cause pneumonia, endocarditis, meningitis, encephalitis, or disseminated intravascular coagulation.
The diagnosis of Exophialaxenobiotica is based on the fungus’s separation and identification from clinical specimens, such as skin scrapings, biopsies, blood, or cerebrospinal fluid. Techniques involving molecules, including sequencing the internal transcribed spacer (ITS) region, can help to differentiate Exophialaxenobiotica from other closely related species, such as E. jeanselmei.
The morphology of E. xenobiotica is very similar to E. jeanselmei, but it has fewer melanized conidiogenous cells. The antifungal susceptibility testing of E. xenobiotica can be performed by different methods, such as broth microdilution, Etest, or disk diffusion.
The most effective antifungal agents are itraconazole, voriconazole, and posaconazole, while amphotericin B has moderate activity. Exophialaxenobiotica is a relatively common agent of cutaneous infections in humans, whereasE. jeanselmei is associated with subcutaneous infections. Exophialaxenobiotica can also cause systemic infections in immunocompromised hosts.
The prevention of Exophiala xenobiotica infections is not well established, but some general measures may help to lower the chance of infection and exposure. These include:
Avoiding contact with contaminated environments, such as oil-contaminated soils, wastewater, and biofilters.
Wearing protective gloves, clothing, and masks when handling or working with hydrocarbons and alkanes.
Practicing good hygiene and wound care, especially after traumatic injuries or surgical procedures.
Seeking medical attention promptly if any signs or symptoms of infection develop, such as skin lesions, fever, cough, chest pain, or neurological problems.
Taking antifungal prophylaxis if immunocompromised or having chronic lung diseases, such as cystic fibrosis.
Following the prescribed antifungal treatment regimen and monitoring the response to therapy.
The epidemiology of Exophiala xenobiotica needs to be better understood. Still, some studies have suggested that it is widely distributed in the environment, especially in habitats rich in hydrocarbons and alkanes, such as oil-contaminated soils, wastewater, and biofilters. It has also been detected in the respiratory tracts of cystic fibrosis patients. and the skin of fish. The prevalence of Exophiala xenobiotica infections is likely underestimated, as it is morphologically very similar to E. jeanselmei and requires molecular methods for accurate identification.
The risk factors for acquiring Exophiala xenobiotica infections are not well defined, but they may include exposure to contaminated environments, immunosuppression, chronic lung diseases, and surgical procedures. The global distribution and incidence of Exophiala xenobiotica infections are unknown, but most cases have been reported in Europe, Asia, and North America. More studies are needed to elucidate the ecology, transmission, and pathogenicity of this emerging fungal agent.
The prevalence and mortality rate of Exophiala xenobiotica infections has yet to be well known, as this is a relatively new species that was described in 2006. However, some studies have reported a few cases of human and animal infections caused by this fungus. For example, a study from India identified one isolate of E. xenobiotica among 24 Exophiala isolates from various clinical specimens.
Another study from China reported two cases of cutaneous infections by E. xenobiotica in immunocompetent patients. A third study from Germany described a case of fatal disseminated infection by E. xenobiotica in a patient with chronic granulomatous disease. The mortality rate of E. xenobiotica infections may depend on the type and extent of infection, the immune status of the host, and the response to antifungal therapy.
Classification and Structure
Kingdom: Fungi
Phylum: Ascomycota
Class: Eurotiomycetes
Order: Chaetothyriales
Family: Herpotrichiellaceae
Genus:Exophiala
Species: E. xenobiotica
The structure of Exophiala xenobiotica can be summarized in five points as follows:
Exophiala xenobiotica is a species of black yeast that belongs to the Exophiala jeanselmei complex.
It produces black, velvety colonies on Sabouraud dextrose agar and has darkly pigmented, annellidic conidiogenous cells and oval to cylindrical conidia.
It has a protein crystal structure of an amine transaminase, which is an enzyme that catalyzes the conversion of biaryl ketones to amines.
It has two antigenic types, A and B, according to the internal transcribed spacer (ITS) region’s sequence analysis of the ribosomal DNA. Type A is more common and widely distributed than type B.
It is phylogenetically related to other Exophiala species and other members of the Herpotrichiellaceae family, which are opportunistic black yeast-like fungi.
The antigenic types of Exophialaxenobiotica are not well studied, but based on the results from the web search; it seems that this species is a segregant of the Exophialajeanselmeicomplex, which has two antigenic types: type A and The ITS sequence phylogram of E. jeanselmei revealed that most isolates formed a separate cluster close to type A, while some isolates were like type B.
E. xenobiotica may have a similar antigenic diversity, but more research is needed to confirm this hypothesis. Antigenic types are essential for the diagnosis and treatment of Exophiala infections, as they may reflect different virulence and antifungal susceptibility patterns.
The pathogenesis of Exophialaxenobiotica is not well understood, but it is known that it can cause cutaneous infections in humans, especially in immunocompromised individuals. It can also infect animals, such as crocodile fish and rabbit fish, and cause systemic infections of the liver and kidney.
The fungus may enter the host through wounds or abrasions on the skin or through inhalation of spores. It may produce toxins or enzymes that damage the host tissues or evade the host immune system by forming melanin pigments or biofilms.
The fungus may also have different antigenic types, A and B, that may affect its pathogenicity, ecology, and epidemiology. However, more studies are needed to confirm this hypothesis and to elucidate the molecular mechanisms of infection byExophialaxenobiotica.
The host defenses to Exophiala xenobiotica are not well studied, but some general aspects of the immune response to black yeasts can be mentioned. Black yeasts can evade or resist the host defenses by producing melanin pigments, biofilms, and extracellular enzymes. Melanin protects the fungal cells from oxidative stress, phagocytosis, and antifungal drugs.
Biofilms enhance the adherence and persistence of the fungus on the host surfaces and reduce the penetration of antimicrobial agents1. Extracellular enzymes, such as lipases, proteases, and phospholipases, may degrade the host tissues and facilitate the invasion and dissemination of the fungus.
The host defenses against black yeasts involve both innate and adaptive immunity. Skin and mucous membranes are examples of physical barriers that are a part of innate immunity and cellular and molecular components, such as neutrophils, macrophages, natural killer cells, complement, and cytokines. The adaptive immunity includes humoral and cellular responses, like T cells, B cells, and antibodies.
The role of these immune components in the defense against Exophiala xenobiotica needs to be clarified. Still, some studies have suggested that T lymphocytes, neutrophils, and macrophages could all be involved in the clearance or containment of the infection. However, the immune response may also cause tissue damage and inflammation, which may contribute to the pathogenesis of the infection.
The host defenses to Exophiala xenobiotica may also depend on the host factors, such as the genetic background, the immune status, and the underlying diseases of the host. For example, immunocompromised individuals, such as those with HIV infection, organ transplantation, or cancer, may have a higher susceptibility and a worse prognosis of the infection.
On the other hand, some individuals may have a natural resistance or protective immunity to the infection, which may be related to their genetic polymorphisms or previous exposure to the fungus.Therefore, the host defenses to Exophiala xenobiotica are complex and variable, and more research is needed to comprehend the components and processes involved in the interaction between the host and the fungus.
Black yeast Exophiala xenobiotica is a member of the Exophiala jeanselmei complex. This pathogen is opportunistic and can infect both humans and animals, especially in immunocompromised hosts.
The clinical manifestations of Exophiala xenobiotica infections differ according to the location and severity of the infection. Several potential expressions
are:
Cutaneous infections: These are usually caused by traumatic inoculation of the fungus into the skin. They can present as nodules, ulcers, verrucous lesions, or cysts. Sometimes, the lesions can mimic benign epidermoid cysts.
Subcutaneous infections: These are deeper infections that involve the subcutaneous tissue, muscle, or bone. They can result from direct extension of cutaneous infections or hematogenous dissemination. They can cause mycetoma, osteomyelitis, arthritis, or abscesses.
Systemic infections: These are rare but life-threatening infections that impact several organs, including the lungs, liver, spleen, brain, kidneys, and heart. They can cause pneumonia, endocarditis, meningitis, encephalitis, or disseminated intravascular coagulation.
The diagnosis of Exophialaxenobiotica is based on the fungus’s separation and identification from clinical specimens, such as skin scrapings, biopsies, blood, or cerebrospinal fluid. Techniques involving molecules, including sequencing the internal transcribed spacer (ITS) region, can help to differentiate Exophialaxenobiotica from other closely related species, such as E. jeanselmei.
The morphology of E. xenobiotica is very similar to E. jeanselmei, but it has fewer melanized conidiogenous cells. The antifungal susceptibility testing of E. xenobiotica can be performed by different methods, such as broth microdilution, Etest, or disk diffusion.
The most effective antifungal agents are itraconazole, voriconazole, and posaconazole, while amphotericin B has moderate activity. Exophialaxenobiotica is a relatively common agent of cutaneous infections in humans, whereasE. jeanselmei is associated with subcutaneous infections. Exophialaxenobiotica can also cause systemic infections in immunocompromised hosts.
The prevention of Exophiala xenobiotica infections is not well established, but some general measures may help to lower the chance of infection and exposure. These include:
Avoiding contact with contaminated environments, such as oil-contaminated soils, wastewater, and biofilters.
Wearing protective gloves, clothing, and masks when handling or working with hydrocarbons and alkanes.
Practicing good hygiene and wound care, especially after traumatic injuries or surgical procedures.
Seeking medical attention promptly if any signs or symptoms of infection develop, such as skin lesions, fever, cough, chest pain, or neurological problems.
Taking antifungal prophylaxis if immunocompromised or having chronic lung diseases, such as cystic fibrosis.
Following the prescribed antifungal treatment regimen and monitoring the response to therapy.
The epidemiology of Exophiala xenobiotica needs to be better understood. Still, some studies have suggested that it is widely distributed in the environment, especially in habitats rich in hydrocarbons and alkanes, such as oil-contaminated soils, wastewater, and biofilters. It has also been detected in the respiratory tracts of cystic fibrosis patients. and the skin of fish. The prevalence of Exophiala xenobiotica infections is likely underestimated, as it is morphologically very similar to E. jeanselmei and requires molecular methods for accurate identification.
The risk factors for acquiring Exophiala xenobiotica infections are not well defined, but they may include exposure to contaminated environments, immunosuppression, chronic lung diseases, and surgical procedures. The global distribution and incidence of Exophiala xenobiotica infections are unknown, but most cases have been reported in Europe, Asia, and North America. More studies are needed to elucidate the ecology, transmission, and pathogenicity of this emerging fungal agent.
The prevalence and mortality rate of Exophiala xenobiotica infections has yet to be well known, as this is a relatively new species that was described in 2006. However, some studies have reported a few cases of human and animal infections caused by this fungus. For example, a study from India identified one isolate of E. xenobiotica among 24 Exophiala isolates from various clinical specimens.
Another study from China reported two cases of cutaneous infections by E. xenobiotica in immunocompetent patients. A third study from Germany described a case of fatal disseminated infection by E. xenobiotica in a patient with chronic granulomatous disease. The mortality rate of E. xenobiotica infections may depend on the type and extent of infection, the immune status of the host, and the response to antifungal therapy.
Classification and Structure
Kingdom: Fungi
Phylum: Ascomycota
Class: Eurotiomycetes
Order: Chaetothyriales
Family: Herpotrichiellaceae
Genus:Exophiala
Species: E. xenobiotica
The structure of Exophiala xenobiotica can be summarized in five points as follows:
Exophiala xenobiotica is a species of black yeast that belongs to the Exophiala jeanselmei complex.
It produces black, velvety colonies on Sabouraud dextrose agar and has darkly pigmented, annellidic conidiogenous cells and oval to cylindrical conidia.
It has a protein crystal structure of an amine transaminase, which is an enzyme that catalyzes the conversion of biaryl ketones to amines.
It has two antigenic types, A and B, according to the internal transcribed spacer (ITS) region’s sequence analysis of the ribosomal DNA. Type A is more common and widely distributed than type B.
It is phylogenetically related to other Exophiala species and other members of the Herpotrichiellaceae family, which are opportunistic black yeast-like fungi.
The antigenic types of Exophialaxenobiotica are not well studied, but based on the results from the web search; it seems that this species is a segregant of the Exophialajeanselmeicomplex, which has two antigenic types: type A and The ITS sequence phylogram of E. jeanselmei revealed that most isolates formed a separate cluster close to type A, while some isolates were like type B.
E. xenobiotica may have a similar antigenic diversity, but more research is needed to confirm this hypothesis. Antigenic types are essential for the diagnosis and treatment of Exophiala infections, as they may reflect different virulence and antifungal susceptibility patterns.
The pathogenesis of Exophialaxenobiotica is not well understood, but it is known that it can cause cutaneous infections in humans, especially in immunocompromised individuals. It can also infect animals, such as crocodile fish and rabbit fish, and cause systemic infections of the liver and kidney.
The fungus may enter the host through wounds or abrasions on the skin or through inhalation of spores. It may produce toxins or enzymes that damage the host tissues or evade the host immune system by forming melanin pigments or biofilms.
The fungus may also have different antigenic types, A and B, that may affect its pathogenicity, ecology, and epidemiology. However, more studies are needed to confirm this hypothesis and to elucidate the molecular mechanisms of infection byExophialaxenobiotica.
The host defenses to Exophiala xenobiotica are not well studied, but some general aspects of the immune response to black yeasts can be mentioned. Black yeasts can evade or resist the host defenses by producing melanin pigments, biofilms, and extracellular enzymes. Melanin protects the fungal cells from oxidative stress, phagocytosis, and antifungal drugs.
Biofilms enhance the adherence and persistence of the fungus on the host surfaces and reduce the penetration of antimicrobial agents1. Extracellular enzymes, such as lipases, proteases, and phospholipases, may degrade the host tissues and facilitate the invasion and dissemination of the fungus.
The host defenses against black yeasts involve both innate and adaptive immunity. Skin and mucous membranes are examples of physical barriers that are a part of innate immunity and cellular and molecular components, such as neutrophils, macrophages, natural killer cells, complement, and cytokines. The adaptive immunity includes humoral and cellular responses, like T cells, B cells, and antibodies.
The role of these immune components in the defense against Exophiala xenobiotica needs to be clarified. Still, some studies have suggested that T lymphocytes, neutrophils, and macrophages could all be involved in the clearance or containment of the infection. However, the immune response may also cause tissue damage and inflammation, which may contribute to the pathogenesis of the infection.
The host defenses to Exophiala xenobiotica may also depend on the host factors, such as the genetic background, the immune status, and the underlying diseases of the host. For example, immunocompromised individuals, such as those with HIV infection, organ transplantation, or cancer, may have a higher susceptibility and a worse prognosis of the infection.
On the other hand, some individuals may have a natural resistance or protective immunity to the infection, which may be related to their genetic polymorphisms or previous exposure to the fungus.Therefore, the host defenses to Exophiala xenobiotica are complex and variable, and more research is needed to comprehend the components and processes involved in the interaction between the host and the fungus.
Black yeast Exophiala xenobiotica is a member of the Exophiala jeanselmei complex. This pathogen is opportunistic and can infect both humans and animals, especially in immunocompromised hosts.
The clinical manifestations of Exophiala xenobiotica infections differ according to the location and severity of the infection. Several potential expressions
are:
Cutaneous infections: These are usually caused by traumatic inoculation of the fungus into the skin. They can present as nodules, ulcers, verrucous lesions, or cysts. Sometimes, the lesions can mimic benign epidermoid cysts.
Subcutaneous infections: These are deeper infections that involve the subcutaneous tissue, muscle, or bone. They can result from direct extension of cutaneous infections or hematogenous dissemination. They can cause mycetoma, osteomyelitis, arthritis, or abscesses.
Systemic infections: These are rare but life-threatening infections that impact several organs, including the lungs, liver, spleen, brain, kidneys, and heart. They can cause pneumonia, endocarditis, meningitis, encephalitis, or disseminated intravascular coagulation.
The diagnosis of Exophialaxenobiotica is based on the fungus’s separation and identification from clinical specimens, such as skin scrapings, biopsies, blood, or cerebrospinal fluid. Techniques involving molecules, including sequencing the internal transcribed spacer (ITS) region, can help to differentiate Exophialaxenobiotica from other closely related species, such as E. jeanselmei.
The morphology of E. xenobiotica is very similar to E. jeanselmei, but it has fewer melanized conidiogenous cells. The antifungal susceptibility testing of E. xenobiotica can be performed by different methods, such as broth microdilution, Etest, or disk diffusion.
The most effective antifungal agents are itraconazole, voriconazole, and posaconazole, while amphotericin B has moderate activity. Exophialaxenobiotica is a relatively common agent of cutaneous infections in humans, whereasE. jeanselmei is associated with subcutaneous infections. Exophialaxenobiotica can also cause systemic infections in immunocompromised hosts.
The prevention of Exophiala xenobiotica infections is not well established, but some general measures may help to lower the chance of infection and exposure. These include:
Avoiding contact with contaminated environments, such as oil-contaminated soils, wastewater, and biofilters.
Wearing protective gloves, clothing, and masks when handling or working with hydrocarbons and alkanes.
Practicing good hygiene and wound care, especially after traumatic injuries or surgical procedures.
Seeking medical attention promptly if any signs or symptoms of infection develop, such as skin lesions, fever, cough, chest pain, or neurological problems.
Taking antifungal prophylaxis if immunocompromised or having chronic lung diseases, such as cystic fibrosis.
Following the prescribed antifungal treatment regimen and monitoring the response to therapy.
Both our subscription plans include Free CME/CPD AMA PRA Category 1 credits.
Digital Certificate PDF
On course completion, you will receive a full-sized presentation quality digital certificate.
medtigo Simulation
A dynamic medical simulation platform designed to train healthcare professionals and students to effectively run code situations through an immersive hands-on experience in a live, interactive 3D environment.
medtigo Points
medtigo points is our unique point redemption system created to award users for interacting on our site. These points can be redeemed for special discounts on the medtigo marketplace as well as towards the membership cost itself.
Community Forum post/reply = 5 points
*Redemption of points can occur only through the medtigo marketplace, courses, or simulation system. Money will not be credited to your bank account. 10 points = $1.
All Your Certificates in One Place
When you have your licenses, certificates and CMEs in one place, it's easier to track your career growth. You can easily share these with hospitals as well, using your medtigo app.
